Bristol-Myers Squibb (NYSE:BMY) PT Lowered to $48.00

Bristol-Myers Squibb (NYSE:BMY) had its price target dropped by investment analysts at BMO Capital Markets from $55.00 to $48.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 7.02% from the company’s previous close.

A number of other equities research analysts have also issued reports on BMY. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, Barclays decreased their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Trading Up 0.3 %

Bristol-Myers Squibb stock opened at $44.85 on Friday. The company has a 50 day moving average price of $51.03 and a 200 day moving average price of $51.14. Bristol-Myers Squibb has a 52 week low of $44.34 and a 52 week high of $69.10. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The firm has a market capitalization of $90.90 billion, a price-to-earnings ratio of -14.47, a P/E/G ratio of 16.25 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 50.04%. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the business posted $2.05 EPS. The company’s revenue was up 4.7% on a year-over-year basis. Research analysts forecast that Bristol-Myers Squibb will post 0.55 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BMY. OFI Invest Asset Management bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $25,000. Milestone Investment Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $27,000. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $27,000. Blue Bell Private Wealth Management LLC increased its holdings in shares of Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares during the period. Finally, Accordant Advisory Group Inc bought a new position in shares of Bristol-Myers Squibb during the 1st quarter worth about $31,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.